ImageneBio Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Public

  • Employees
  • 22

Employees

  • Stock Symbol
  • IMA

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $3.47
  • (As of Friday Closing)

ImageneBio General Information

Description

ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.

Contact Information

Website
www.imagenebio.com
Formerly Known As
Ikena Oncology
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 12526 High Bluff Drive
  • Suite 345
  • San Diego, CA 92130
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 12526 High Bluff Drive
  • Suite 345
  • San Diego, CA 92130
  • United States
+1 (858)

ImageneBio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImageneBio Stock Performance

As of 13-Nov-2026, ImageneBio’s stock price is $3.47. Its current market cap is $43.2M with 12.5M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.47 $3.45 $3.34 - $8.32 $43.2M 12.5M 13.4K -$2.11

ImageneBio Financials Summary

As of 30-Sep-2026, ImageneBio has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (82,251) (61,984)
Revenue 0 800 3,500 7,962
EBITDA (47,327) (46,701) (35,403) (18,967)
Net Income (43,325) (45,349) (36,568) (21,148)
Total Assets 142,541 152,976 15,922 31,245
Total Debt 1,312 2,975 8,048 983
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ImageneBio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ImageneBio‘s full profile, request access.

Request a free trial

ImageneBio Patents

  • 98

    Total Documents Applications and Grants

  • Total Patents Families

  • 13

    Granted

  • 17

    Pending

  • Expiring in next 12 mo

ImageneBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024243025-A1 Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions Inactive 19-May-2023
WO-2024220470-A1 Tead inhibitors and uses thereof in the treatment of proliferative disorders Inactive 17-Apr-2023
WO-2024173761-A1 Combinations comprising mek inhibitors for use in the treatment of cancer Inactive 17-Feb-2023
WO-2024092116-A1 Combination of tead inhibitors and egfr inhibitors and uses thereof Inactive 26-Oct-2022
WO-2024064335-A1 Naphthyl-substituted pyranopyrimidinones and related compounds and their use in treating medical conditions Inactive 23-Sep-2022 A61P35/00
To view ImageneBio’s complete patent history, request access »

ImageneBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImageneBio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ImageneBio‘s full profile, request access.

Request a free trial

ImageneBio Acquisitions (1)

ImageneBio’s most recent deal was a Merger/Acquisition with Ikena Oncology. The deal was made on 25-Jul-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Ikena Oncology 25-Jul-2025 Merger/Acquisition Drug Discovery
To view ImageneBio’s complete acquisitions history, request access »

ImageneBio ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view ImageneBio’s complete esg history, request access »

ImageneBio FAQs

  • When was ImageneBio founded?

    ImageneBio was founded in 2016.

  • Where is ImageneBio headquartered?

    ImageneBio is headquartered in San Diego, CA.

  • What is the size of ImageneBio?

    ImageneBio has 22 total employees.

  • What industry is ImageneBio in?

    ImageneBio’s primary industry is Drug Discovery.

  • Is ImageneBio a private or public company?

    ImageneBio is a Public company.

  • What is ImageneBio’s stock symbol?

    The ticker symbol for ImageneBio is IMA.

  • What is the current stock price of ImageneBio?

    As of 13-Nov-2026 the stock price of ImageneBio is $3.47.

  • What is the current market cap of ImageneBio?

    The current market capitalization of ImageneBio is $43.2M.

  • What is ImageneBio’s annual earnings per share (EPS)?

    ImageneBio’s EPS for 12 months was -$2.11.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process